NEW YORK (GenomeWeb News) – Myriad Genetics said this week that BioMarin Pharmaceutical will use its BRACAnalysis test in its pivotal Phase 3 clinical study for BMN 673, an orally active PARP-inhibitor designed to induce synthetic lethality in BRCA-deficient cells. Myriad has submitted an Investigational Device Exemption to the US Food and Drug Administration that would allow the BRACAnalysis test to be used as a companion diagnostic to stratify patients in the BMN 673 clinical program, as required by FDA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.